Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer

Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Ryuji Hamamoto, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Background/Aim: Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is deeply involved in the pathogenesis of lung cancer. We evaluated the metabolic characteristics of non-small cell lung cancer (NSCLC) in patients with and without expression of EZH2 using 18Ffluorodeoxyglucose positron-emission tomography/ computed tomography (18F-FDG PET/CT). Materials and Methods: The EZH2 protein expression of 268 patients with resected NSCLC, whose preoperative 18F-FDG PET/CT information was available, was evaluated by immunohistochemistry with clone 6A10 antibody; cases with Allred score 3 were considered positive. Results: Maximized standard uptake values in cases of EZH2-positive NSCLC and adenocarcinoma were significantly higher in comparison to EZH2-negative cases (p<0.001, and p<0.001, respectively). The expression of EZH2 in NSCLC and adenocarcinoma was associated with significantly poorer survival. Conclusion: In patients with NSCLC and adenocarcinoma, EZH2 positivity was associated with a high uptake of FDG, suggesting that EZH2 might define metabolically malignant lung cancer.

Original languageEnglish
Pages (from-to)1393-1401
Number of pages9
JournalAnticancer research
Volume37
Issue number3
DOIs
Publication statusPublished - Mar 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Elevated metabolic activity on 18f-fdg pet/ct is associated with the expression of ezh2 in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this